FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
WASHINGTON (AP) — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic.
Moderna is seeking Food and Drug Administration approval of its new shot, dubbed mFlusiva, as an option for people 50 and older.
The FDA […] ...
이 뉴스, 독자들은 어떻게 느꼈나요?
첫 반응을 남겨보세요로그인하면 감정 반응에 참여할 수 있어요.